arrow_back Back to App

Tax Credits for US Generic Drug and Biosimilar Production

This new law introduces tax credits for companies manufacturing generic drugs and biosimilars in the United States. The aim is to increase the availability and lower the cost of these medicines, potentially impacting citizens' healthcare expenses. Additionally, the act supports investments in new production facilities within the USA.
Key points
Companies producing generic drugs and biosimilars in the US will receive tax credits, potentially lowering drug prices.
Support for domestic drug production aims to enhance supply security and reduce reliance on foreign manufacturers.
The act provides additional benefits for companies using US-made components in drug production.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1396
Sponsor: Rep. Tenney, Claudia [R-NY-24]
Process start date: 2025-02-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PILLS Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1396.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-14.

What are the main provisions?

Key points include:

  • Companies producing generic drugs and biosimilars in the US will receive tax credits, potentially lowering drug prices.
  • Support for domestic drug production aims to enhance supply security and reduce reliance on foreign manufacturers.
  • The act provides additional benefits for companies using US-made components in drug production.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Tenney, Claudia [R-NY-24].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Ways and Means.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Taxes Economy